Amivantamab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
No
Active ingredient: Amivantamab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combination with platinum-based chemotherapy for inclusion on the MOH List of Subsidised Drugs for previously untreated, locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive non-small-cell lung cancer. The decision was based on the uncertain extent of clinical benefit, unfavourable cost effectiveness compared with platinum-based chemotherapy, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for amivantamab are provided in the Annex.
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combination with platinum-based chemotherapy, for inclusion on the MOH List of Subsidised Drugs for previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer. The decision was based on the uncertain extent of clinical benefit, unfavourable cost-effectiveness compared with platinum-based chemotherapy, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for amivantamab are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals (opens in new tab) or Polyclinics (opens in new tab) for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Rybrevant Infusion, Solution Concentrate 350 mg/7 mL |
|